Theravance Biopharma, Inc. Cash Provided by (Used in) Financing Activities, Discontinued Operations
Theravance Biopharma, Inc. (TBPH) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of -$20.19 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2024-03-01
- Theravance Biopharma, Inc. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2022-12-31 was $0.00.
- Theravance Biopharma, Inc. cash provided by (used in) financing activities, discontinued operations for fiscal 2022 was -$20.19M.
- Theravance Biopharma, Inc. cash provided by (used in) financing activities, discontinued operations for fiscal 2020 was -$16.80M.
| Period end | Cash Provided by (Used in) Financing Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$20.19M 10-K · filed 2024-03-01 | |
| 2022-09-30 | -$20.19M 10-Q · filed 2023-11-09 | ||
| 2020-12-31 | -$16.80M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |